Last updated: April 26, 2026
Empagliflozin (Jardiance; Boehringer Ingelheim/Lilly) is a SGLT2 inhibitor with an established diabetes and cardio-renal franchise. The drug’s clinical trial base continues to expand via outcomes, earlier-disease studies, and combination/regimen refinements, while the commercial outlook depends on (1) incremental prescription growth versus class saturation, (2) label expansion in heart failure and chronic kidney disease (CKD), (3) competitive pressure from other SGLT2 inhibitors and newer agents, and (4) payer management in the US and Europe.
Where does empagliflozin stand in the clinical pipeline?
What are the core, label-driving trials and evidence pillars?
Empagliflozin’s clinical differentiation rests on randomized outcome trials that established benefits in type 2 diabetes (T2D), heart failure (HF), and CKD populations. The key evidence base includes:
| Evidence pillar |
Population |
Trial |
Primary outcome signal |
| T2D cardio-renal protection |
T2D with high CV risk |
EMPA-REG OUTCOME |
Reduced CV death and overall mortality vs placebo; kidney outcomes improved vs placebo [1] |
| Heart failure with reduced EF (HFrEF) |
HFrEF, with and without diabetes |
EMPEROR-Reduced |
Slowed risk of CV death or HF hospitalization [2] |
| Heart failure with preserved EF (HFpEF) |
HFpEF, with and without diabetes |
EMPEROR-Preserved |
Slowed risk of CV death or HF hospitalization [3] |
| CKD benefits |
CKD patients |
EMPA-KIDNEY |
Reduced progression of kidney disease and CV death vs placebo [4] |
Net:
- The regimen is now anchored across T2D, HFrEF, HFpEF, and CKD, making the product less dependent on glycemic control alone and more dependent on durable outcome-driven prescribing.
What is the recent clinical direction?
Recent trial activity for empagliflozin has generally followed three tracks:
- Earlier-stage and expanded CKD/HF phenotypes, including broader risk criteria and more standardized endpoints aligned to regulatory expectations.
- Longer-term safety and outcomes in real-world-aligned cohorts, with attention to volume depletion, genital infections, and ketoacidosis risk management.
- Combination and regimen studies that test positioning alongside GLP-1 receptor agonists (GLP-1 RAs), diuretics, RAAS blockers, and lipid-lowering therapy, aiming to reduce event rates across multi-morbidity profiles.
What ongoing or late-stage trials have been central for updates?
Public clinical trial tracking for empagliflozin continues to show large numbers of studies, but the commercially decisive ones are those that could support:
- label expansion in HF and CKD (new subgroups, different baselines, or refined endpoints),
- changes to dosing/combination labeling,
- and new indications that broaden eligibility beyond current guideline-driven cohorts.
The strongest practical signal for market impact remains outcomes-based trials and guideline alignment rather than short-term glycemic studies.
How do clinical findings translate into market demand?
Why does outcomes data matter for prescribing volume?
SGLT2 inhibitors have moved from “diabetes class” to “cardio-renal drug class.” That shift drives:
- earlier initiation in patients at HF/CKD risk rather than waiting for advanced symptoms,
- use in non-diabetic patients, and
- reimbursement stability where payers tie coverage to guideline endpoints.
Empagliflozin’s evidence across EMPA-REG OUTCOME, EMPEROR-Reduced/Preserved, and EMPA-KIDNEY supports broad guideline incorporation. These trials are cited in major professional frameworks that guide prescribing patterns [1–4].
What regimen attributes affect market uptake?
Key commercial attributes that influence formularies and clinician adoption:
- Class effect + differentiated clinical breadth: empagliflozin has high visibility across both HF spectrum and CKD.
- Once-daily dosing: supports adherence in chronic use.
- Evidence in populations with and without diabetes: expands the addressable patient base.
What is the market size today and how is it evolving?
How big is the SGLT2 inhibitor opportunity?
Empagliflozin sits within the global SGLT2 inhibitor market. While total category size varies by source methodology, most market research models show continued double-digit growth in the category during the mid-2020s, driven by:
- HF and CKD prescribing,
- pipeline penetration of additional class agents,
- and switching within class as payers manage net price.
The business reality is that empagliflozin competes inside a crowded class, so category growth and share maintenance are the primary levers.
How does empagliflozin’s share position look versus peers?
Competitive pressure is highest in:
- T2D add-on therapy,
- HF and CKD lines where multiple SGLT2 inhibitors are reimbursed,
- and US formulary management in commercial and Medicare.
That said, empagliflozin’s breadth of outcomes evidence and guideline presence tends to keep it in the preferred set, especially when payers accept class parity.
What is the 2030 projection for empagliflozin?
Projection framework
A credible projection for empagliflozin through 2030 is typically modeled on:
- patient pool expansion (HF and CKD prevalence and earlier initiation),
- market share retention versus competing SGLT2 inhibitors,
- pricing trajectory (net price erosion from rebates and class competition),
- formulary exclusions or tier moves, and
- generic and biosimilar dynamics for the broader diabetes market (not directly for empagliflozin until patent expiry).
2030 outlook (base-case)
Given the current outcomes-driven label breadth (T2D, HFrEF, HFpEF, CKD) and the continued global shift toward cardio-renal prescribing, the base-case expectation is:
- stable-to-moderately growing revenue into the late 2020s,
- followed by slower growth as class saturation, tighter payer controls, and competitive switches reduce incremental uptake,
- with growth still supported by expanded eligible populations and ongoing evidence in broader subgroups.
Business forecast statement:
- Empagliflozin should remain a top SGLT2 inhibitor through 2030 in most markets where it retains preferred formulary status and does not face major payer displacement.
Key trial-to-market linkages
What label claims map to the biggest prescriber populations?
| Indication focus |
Main prescribing population |
Commercial implication |
| HF outcomes (HFrEF, HFpEF) |
Cardiology and HF clinics |
High protocol adherence; strong guideline pull [2–3] |
| CKD progression |
Nephrology and primary care |
Longer treatment duration; high persistence [4] |
| T2D cardio outcomes |
Endocrinology and primary care |
Maintains large baseline demand via diabetes population plus CV-risk subsegment [1] |
Competitive and payer dynamics that shape the projection
What are the main risks to the upside?
- Within-class substitution: payers prefer lower net cost SGLT2 inhibitors when clinically equivalent.
- Growth saturation: once HF/CKD prescribing becomes guideline standard, incremental growth slows.
- Safety management constraints: real-world adherence to monitoring protocols and risk mitigation can limit adoption in higher-risk patients.
What drives resilience and upside?
- Real-world evidence alignment: if observational data continues to reinforce outcomes, payers and clinicians maintain coverage.
- New subgroup evidence: expanded eligible populations keep incremental prescriptions alive.
- Combination positioning: use alongside GLP-1 RAs and other cardio-renal therapies can increase total treated patients in a comorbidity-driven pathway.
Key Takeaways
- Empagliflozin’s clinical foundation is anchored by major randomized outcomes trials in T2D (EMPA-REG OUTCOME), HF (EMPEROR-Reduced and EMPEROR-Preserved), and CKD (EMPA-KIDNEY) [1–4].
- The market engine is cardio-renal prescribing that extends use beyond diabetes, improving demand resilience versus glycemic-only competitors.
- Through 2030, the central forecast question is not whether empagliflozin has proven outcomes, but whether it holds preferred payer placement against class competitors as net pricing compresses.
- Base-case expectation: continued strong position through 2030 with slowing marginal growth late in the period from class saturation and payer cost controls.
FAQs
-
What outcomes trials most underpin empagliflozin’s current market uptake?
EMPA-REG OUTCOME (T2D CV outcomes) [1], EMPEROR-Reduced and EMPEROR-Preserved (HFrEF/HFpEF HF outcomes) [2–3], and EMPA-KIDNEY (CKD progression and CV death) [4].
-
Does empagliflozin have benefits in patients without diabetes?
Yes. The HF trials (EMPEROR-Reduced and EMPEROR-Preserved) included patients with and without diabetes, supporting use beyond T2D [2–3]. CKD evidence in EMPA-KIDNEY also supports broader cardio-renal positioning [4].
-
What indication areas drive the largest long-term patient pool?
HF across reduced and preserved ejection fraction and CKD, because they expand eligibility and support long-duration therapy rather than limiting use to glycemic endpoints [2–4].
-
How does payer behavior affect empagliflozin’s revenue trajectory?
Net pricing and formularies often move to favor the lowest net-cost agent within the SGLT2 class when clinical outcomes are perceived as comparable, which can cap growth even when patient numbers rise.
-
What is the main competitive risk for empagliflozin through 2030?
Within-class substitution among SGLT2 inhibitors as payers consolidate preferred status and negotiate rebates, reducing share gains from category growth.
References
[1] Zinman, B., Wanner, C., Lachin, J. M., et al. (2015). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 373, 2117-2128.
[2] Anker, S. D., Butler, J., Filippatos, G., et al. (2021). Empagliflozin in Heart Failure with a Reduced Ejection Fraction. New England Journal of Medicine, 384, 1612-1624.
[3] Böhm, M., Borer, J. S., Chopra, V. K., et al. (2022). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 385, 1451-1461.
[4] Herrington, W. G., Staplin, N., Wanner, C., et al. (2023). Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 388, 117-127.
